E. Small

Publications748
h-index99
Citations46,439
Highly Influential Citations1,657
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • H. Scher
  • 898 Publications, 75,494 Citations
  • J. D. de Bono
  • 470 Publications, 43,353 Citations
  • P. Kantoff
  • 751 Publications, 55,296 Citations
  • C. Ryan
  • 411 Publications, 13,729 Citations
  • Publications
  • Influence
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
BACKGROUND Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. … Expand
  • 4,112
  • 159
  • PDF
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
BACKGROUND Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with… Expand
  • 3,331
  • 142
  • PDF
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
PURPOSE To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone. METHODS A committee… Expand
  • 1,734
  • 84
  • PDF
Activation of Cardiac Gene Expression by Myocardin, a Transcriptional Cofactor for Serum Response Factor
Serum response factor (SRF) regulates transcription of numerous muscle and growth factor-inducible genes. Because SRF is not muscle specific, it has been postulated to activate muscle genes by… Expand
  • 824
  • 72
  • PDF
Abiraterone in metastatic prostate cancer without previous chemotherapy.
BACKGROUND Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this… Expand
  • 1,986
  • 69
  • PDF
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
PURPOSE Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against prostatic acid phosphatase. A phase III study was undertaken to evaluate the… Expand
  • 1,000
  • 46
  • PDF
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
PURPOSE Prostate-specific antigen (PSA) is a glycoprotein that is found almost exclusively in normal and neoplastic prostate cells. For patients with metastatic disease, changes in PSA will often… Expand
  • 995
  • 34
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
PURPOSE Bevacizumab is an antibody that binds vascular endothelial growth factor and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-alpha) is the historic standard… Expand
  • 704
  • 33
Prostate Cancer, Version 1.2016.
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease.… Expand
  • 472
  • 32
Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer
Background Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic… Expand
  • 426
  • 26
  • PDF